Skip to main content

Table 2 Comparison of thyroid function in breast cancer patients between prechemotherapy and postchemotherapy (mean ± SD)

From: Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine

Thyroid function

Prechemotherapy (n=180)

Postchemotherapy (n=180)

pvalue

T3 (ng/ml)

1.16±0.27

0.80±0.27

<0.001

T4 (μg/dl)

7.30±1.23

6.87±1.57

<0.001

FT3 (pg/ml)

2.89±0.57

2.10±0.49

<0.001

FT4 (ng/dl)

0.85±0.14

0.90±0.19

0.019

TSH (μIU/ml)

2.78±2.16

1.00±1.31

<0.001

Age (y)

49.8

Clinicopathological features

Number

Tumor size

T0 (impalpable)

7

 

T1 (≤2 cm)

66

 

T2 (>2 cm, ≤5 cm)

90

 

T3 (>5 cm)

12

 

Unknown

5

Tumor grade

I

8

 

II

150

 

III

13

 

Unknown

9

Clinical stage

0

9

 

I

46

 

II

107

 

III

7

 

IV

5

 

Unknown

6

Chemotherapy regimens

TEC

158

 

CEF

13

 

NP

8

 

Unknown

1

  1. TEC: Docetaxel, Epirubicin, Cyclophosphamide.
  2. CEF: Cyclophosphamide, Epirubicin, Fluorouracil.
  3. NP: Navelbine, Cisplati.